Maxygen Licenses Interferon Portfolio to Roche
By Business Review Editor
Pharma Deals Review: Vol 2003 Issue 37 (Table of Contents)
Published: 3 Jun-2003
DOI: 10.3833/pdr.v2003.i37.891 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Maxygen and Roche Holding entered into licensing agreement for worldwide commercialization rights to Maxygen’s lead interferon product candidates for the treatment of hepatitis B and hepatitis C viral infections...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS